NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed rights from Health Discovery Corp. and privately held firm Smart Personalized Medicine to develop laboratory tests that help determine appropriate breast cancer therapies.
The firms did not provide details on the licensed technologies. Under the terms of the agreements, Quest will pay health Discovery and SPM upfront licensing payments, development fees, and royalties on a per test basis.
Further terms were not disclosed.
Last year, Savannah, Ga.-based Health Discovery licensed to Quest rights to develop a new urine-based test for clinically significant prostate cancer.